EUVIMEDEUVIMED entdecken
KommentarOpen Access

Long-Term Durability of Active Surveillance of Small, Low-Risk Papillary Thyroid Cancer

Anna M Sawka, Sangeet Ghai, Lorne Rotstein, Jonathan C Irish, Jesse D Pasternak, Eric Monteiro, Janet Chung, Jie Su, Wei Xu, Alex O Esemezie, Jennifer M Jones, Amiram Gafni und 3 weitere

JAMA Surgery · 01.10.2025 · 160 (10) · 1117

DOI: 10.1001/jamasurg.2025.2957 ↗

Kurz gefasst

Kommentar in der Zeitschrift JAMA Surgery, erschienen am 01.10.2025. Verfasst von Anna M Sawka und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, University Health Network and University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Thyroid Cancer, Papillary, Watchful Waiting. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance In managing early-stage cancers, active surveillance (AS) may be preferentially favored by older individuals. In counseling patients, it is important to understand the durability of AS in the context of age.

Objective

To evaluate the durability of AS in patients with small, low-risk papillary thyroid cancer (PTC) according to age at the time of choosing AS. Design, Setting, and Participants This single-center, prospective, long-term follow-up cohort study was conducted at a tertiary care hospital in Toronto, Ontario, Canada. Adult patients with small, localized, low-risk PTC less than 2 cm in maximal diameter were enrolled between May 2016 and February 2021. The clinical outcome data were analyzed up to the time point of May 25, 2025, and final data analysis was performed in June 2025. Exposure All patients were offered the choice of AS or thyroid surgery. Main Outcomes and Measures The primary outcome was the overall rate of AS crossover to definitive treatment (treatment completed or recommended by an investigator) and the indications. Cumulative crossover incidence function curves were examined according to age, with death from other causes as the competing risk.

Results

A total of 200 patients (155 patients under AS and 45 who had immediate surgery) were followed up for a median (IQR) duration of 71 (59-84) months. Overall mean (SD) age was 52.0 (14.9) years, and 153 patients (76.5%) were female. There were no observed thyroid cancer–related deaths or any distant metastatic disease. The overall crossover rate from AS was 23.9% (37/155; 32 completed treatment, 3 declined surgery for disease progression, and 2 awaiting treatment). Crossover reasons included disease progression (56.8% [21/37]), patient preference (40.5% [15/37]), and ultrasound imaging limitations precluding accurate tumor measurement under active surveillance (tumor border not clearly distinguishable from heterogeneous echotexture of the thyroid parenchyma in a patient with Hashimoto thyroiditis; 2.6% [1/37]). The 5-year age-stratified cumulative overall crossover incidence rates were 41.5% (95% CI, 25.6%-56.8%) in patients younger than 45 years, 20.9% (95% CI, 12.3%-31.1%) in those aged 45 to 64 years, and 5.1% (95% CI, 0.9%-15.2%) in those aged 65 years and older ( P < .001). Conclusion and Relevance This single-center Canadian cohort study found that AS is a durable long-term management strategy for small, low -risk PTC, particularly in older individuals. Older individuals may be less likely to cross over to surgery after choosing AS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsThyroid Cancer, PapillaryWatchful WaitingHumansFemaleMaleMiddle AgedAdultProspective StudiesFollow-Up StudiesAge FactorsAgedThyroidectomyOntario

Autor:innen und Institutionen

  • Division of Endocrinology, University Health Network and University of Toronto, Toronto, Ontario, Canada.
  • Joint Department of Medical Imaging, University Health Network-Mt Sinai Hospital-Women's College Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Department of Surgery, University Health Network and University of Toronto, Toronto, Ontario, Canada.
  • Department of Otolaryngology-Head and Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Department of Otolaryngology and Head and Neck Surgery, Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada.
  • Department of Otolaryngology and Head and Neck Surgery, Trillium Health Partners and University of Toronto, Mississauga, Ontario, Canada.

Zitieren

APA

Sawka, A. M., Ghai, S., Rotstein, L., Irish, J. C., Pasternak, J. D., Monteiro, E., Chung, J., Su, J., Xu, W., Esemezie, A. O., Jones, J. M., Gafni, A., Baxter, N. N., Goldstein, D. P., & Canadian Thyroid Cancer Active Surveillance Study Group (Greater Toronto Area) (2025). Long-Term Durability of Active Surveillance of Small, Low-Risk Papillary Thyroid Cancer. JAMA Surgery, 160(10), 1117. https://doi.org/10.1001/jamasurg.2025.2957

Vancouver

Sawka AM, Ghai S, Rotstein L, Irish JC, Pasternak JD, Monteiro E, et al. Long-Term Durability of Active Surveillance of Small, Low-Risk Papillary Thyroid Cancer. JAMA Surgery. 2025;160(10):1117. doi:10.1001/jamasurg.2025.2957

BibTeX
@article{Sawka2025,
  author = {Sawka, Anna M and Ghai, Sangeet and Rotstein, Lorne and Irish, Jonathan C and Pasternak, Jesse D and Monteiro, Eric and Chung, Janet and Su, Jie and Xu, Wei and Esemezie, Alex O and Jones, Jennifer M and Gafni, Amiram and Baxter, Nancy N and Goldstein, David P and Canadian Thyroid Cancer Active Surveillance Study Group (Greater Toronto Area), Canadian Thyroid Cancer Active Surveillance Study Group (Greater Toronto Area)},
  title = {Long-Term Durability of Active Surveillance of Small, Low-Risk Papillary Thyroid Cancer},
  journal = {JAMA Surgery},
  year = {2025},
  volume = {160},
  number = {10},
  pages = {1117},
  doi = {10.1001/jamasurg.2025.2957}
}
Kostenlos starten →